On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019
On track to submit an Investigational New Drug (IND) application for AT845 for Pompe Disease in the third quarter of 2019
Strong balance sheet with December 31, 2018 cash, cash equivalents, marketable securities, and restricted cash of $418.1 million, expected to fund operations into 2021
PR Newswire
SAN FRANCISCO, Feb. 27, 2019